Kestra Medical Technologies Files 8-K

TL;DR

Kestra Medical Tech filed an 8-K on 9/11/25 for financial updates.

AI Summary

Kestra Medical Technologies, Ltd. filed an 8-K on September 11, 2025, reporting on its Results of Operations and Financial Condition, and including Financial Statements and Exhibits. The filing does not contain specific financial figures or operational details within the provided text.

Why It Matters

This 8-K filing indicates that Kestra Medical Technologies is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor company performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting operational and financial information, with no immediate indication of significant risk in the provided text.

Key Players & Entities

• KESTRA MEDICAL TECHNOLOGIES, LTD. (company) — Registrant
• September 11, 2025 (date) — Date of earliest event reported
• 3933 Lake Washington Blvd NE Suite 200 (address) — Principal Executive Offices
• Kirkland, Washington (location) — Principal Executive Offices City and State
• 98033 (zip_code) — Principal Executive Offices Zip Code
• (425) 279-8002 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $1.00 — h registered Common Shares, par value $1.00 per share KMTS The Nasdaq Stock Mar

Filing Documents

• ck0001877184-20250911.htm (8-K) — 49KB
• ck0001877184-ex99_1.htm (EX-99.1) — 259KB
• img39479847_0.jpg (GRAPHIC) — 33KB
• 0000950170-25-114228.txt ( ) — 485KB
• ck0001877184-20250911.xsd (EX-101.SCH) — 33KB
• ck0001877184-20250911_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On September 11, 2025, Kestra Medical Technologies, Ltd. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended July 31, 2025. A copy of the press release, dated September 11, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Kestra Medical Technologies, Ltd., dated September 11, 2025 104 Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kestra Medical Technologies, Ltd. Date: September 11, 2025 By: /s/ Brian Webster Name: Brian Webster Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR